BioCryst gets additional NIAID funding to advance development of BCX4430
These options represent an additional $4.1 million to BioCryst in order to advance the development of BCX4430 as a treatment for hemorrhagic fever viruses. NIAID, part of the
These options represent an additional $4.1 million to BioCryst in order to advance the development of BCX4430 as a treatment for hemorrhagic fever viruses. NIAID, part of the
"The claims included in this Notice of Allowance continue to expand the strength of the VIMOVO patent estate and add to our ability to protect VIMOVO innovation in
The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis(R) PRN ("OHR-102 arm") versus placebo eye drops
Reprogenetics will announce this to clients at the Florida Society of Reproductive Endocrinology and Infertility Meeting (FSREI), Saturday, August 16 at The Ritz-Carlton in Orlando. Rounding out its
To date, there have been no complaints or adverse events reported that can be attributed to the presence of these particles. Evaluations by Amgen found a very low
On the other side of the coin, research suggests that vitamin D could play a role in the prevention and treatment of diabetes, hypertension, glucose intolerance, multiple sclerosis,
FSHD is one of the most common forms of muscular dystrophy and genetic hereditary diseases seen in skeletal muscle. It is estimated that it affects 7 in 100,000
Boehringer Ingelheim Vetmedica has secured the licensing rights for the technology platform Artilysin®. The company is hopeful to receive significant momentum and solutions from this new substance class
The patient was enrolled by one of the trial’s lead principal investigators at a Pituitary Center from a prestigious institution in Baltimore, Maryland. "The enrollment of the first
Designed by The Arthritis Society, the unique pain management program will be rolled out in participating pharmacies in Autumn 2014 under the diem™ therapeutic brand. Pharmacists that have